Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IQE PLC Director's Dealing 2019

Apr 29, 2019

7718_dirs_2019-04-29_9437bbd1-7053-44ce-8446-fde88530bce6.html

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

29 April 2019

IQE plc

(“IQE” or the “Company”)

Director/PDMR Shareholding

IQE plc (AIM: IQE) was notified on 25 April 2019 that Dr Andrew Nelson, Chief Executive Officer of the Company, exercised a total of 7,681,199​ options over ordinary shares of 1 pence each in the Company (“Ordinary Shares”), at a price of 1.000 pence per Ordinary Share on 24 April 2019.

Following the above transaction, Dr Nelson and his persons closely associated hold a beneficial interest of 36,140,417 Ordinary Shares, representing 4.6 per cent. of the Company's issued share capital. Application has now been made to the London Stock Exchange for the admission of 7,681,199 new Ordinary Shares to trading on AIM (“Admission”). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company, with Admission expected to commence on 3 May 2019.

Following Admission, the Company’s issued share capital will consist of 790,503,269 Ordinary Shares, with no Ordinary Shares held in Treasury. Therefore, the total number of voting rights in the Company immediately following Admission will be 790,503,269. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rule

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1. Details of the Person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Dr Andrew Nelson
2. Reason for the notification
a) Position / status PDMR (CEO)
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name IQE plc
b) Legal Entity Identifier 213800Y33WHD3ESJJP16
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument Ordinary shares of 1 pence each in the Company



GB0009619924
b) Nature of the transaction Exercise of options over Ordinary Shares
c) Price(s) and volume(s) 7,681,199 options at 1.000 pence
d) Aggregated information

- Aggregated volume
- Aggregated price
- Aggregated total
7,681,199



1.000 pence



£76,811.99
e) Date of the transaction(s) 24 April 2019
f) Place of the transaction Outside a trading venue

Contacts:

IQE plc

Drew Nelson 

Tim Pullen

Chris Meadows
+44 (0) 29 2083 9400
Canaccord Genuity (Nomad and Joint Broker)

Simon Bridges 

Richard Andrews
+ 44 (0) 20 7523 8000
Peel Hunt (Joint Broker)

Edward Knight

Nick Prowting
+44 (0) 20 7418 8900